IPSEN (OTCMKTS:IPSEY) Upgraded by Barclays to “Hold” Rating

Barclays upgraded shares of IPSEN (OTCMKTS:IPSEY) from a strong sell rating to a hold rating in a research note released on Thursday morning,Zacks reports.

A number of other equities analysts also recently commented on the stock. Zacks Research upgraded shares of IPSEN to a “hold” rating in a research report on Friday, May 29th. Jefferies Financial Group cut IPSEN from a “hold” rating to a “moderate sell” rating in a report on Sunday, August 2nd. Finally, HC Wainwright reissued a “buy” rating on shares of IPSEN in a research note on Tuesday, June 30th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, IPSEN presently has an average rating of “Hold”.

IPSEN Price Performance

Shares of OTCMKTS:IPSEY opened at $44.75 on Thursday. The company’s 50 day moving average is $46.34 and its two-hundred day moving average is $46.70. IPSEN has a 52 week low of $32.02 and a 52 week high of $51.10.

About IPSEN

Ipsen SA is a France-based biopharmaceutical company that develops and commercializes specialty medicines for serious diseases. Its primary focus areas are oncology, rare diseases and neuroscience, with research and development activities aimed at addressing conditions that often have limited treatment options.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected neurological and muscular conditions, and oncology treatments including Cabometyx and Onivyde.